Page 81 - 86_04
P. 81
ANALES 14. McCullagh KG, Davies JA, Sim IS, Dawson KM, O'Neill GJ, Doel SM, et
al. Biological properties of human interferon beta 1 synthesized in re-
RANF combinant bacteria. J Interferon Res 1983;3(1):97–111.
www.analesranf.com 15. Shimizu YK, Oomura M, Abe K, Uno M, Yamada E, Ono Y, et al. Pro-
duction of antibody associated with non-A, non-B hepatitis in a chim-
otras (49). No obstante, entre los principales desafíos a día de hoy panzee lymphoblastoid cell line established by in vitro transformation
se encuentra el de identificar, diagnosticar y tratar a los más de 30 with Epstein-Barr virus. Proc Natl Acad Sci USA. National Academy of
millones de personas infectadas que no han sido diagnosticadas y Sciences 1985; 82(7):2138–42.
que, por lo tanto, desconocen que están infectadas por el virus (49).
16. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Iso-
4. REFERENCIAS lation of a cDNA clone derived from a blood-borne non-A, non-B viral
hepatitis genome. Science 1989; 244(4902):359–62.
1. Foreman KJ, Marquez N, Dolgert A, Fukutaki K, Fullman N, McGaughey
M, et al. Forecasting life expectancy, years of life lost, and all-cause 17. Kuo G, Choo Q, Alter H, Gitnick G, Redeker A, Purcell R, et al. An assay
and cause-specific mortality for 250 causes of death: reference and al- for circulating antibodies to a major etiologic virus of human non-A,
ternative scenarios for 2016-40 for 195 countries and territories. Lancet non-B hepatitis. Science 1989; 244(4902):362–4.
2018; 392(10159):2052–90.
18. Alter HJ, Purcell RH, Shih JW, Melpolder JC, Houghton M, Choo QL, et
2. Guidotti LG, Chisari FV. Immunobiology and pathogenesis of viral he- al. Detection of antibody to hepatitis C virus in prospectively followed
patitis. Annu Rev Pathol 2006; 1 (1):23–61. transfusion recipients with acute and chronic non-A, non-B hepatitis.
N Engl J Med 1989; 321(22):1494–500.
3. Wieland SF, Chisari FV. Stealth and cunning: hepatitis B and hepatitis
C viruses. J Virol 2005; 15: 9369–80. 19. Chien DY, Choo QL, Tabrizi A, Kuo C, McFarland J, Berger K, et al. Diag-
nosis of hepatitis C virus (HCV) infection using an immunodominant
4. Wong DT, Mihm MD, Boyer JL, Jain D. Historical Path of Discovery of chimeric polyprotein to capture circulating antibodies: reevaluation of
Viral Hepatitis. Harvard Medical Student Review 2015; 3:18–36. the role of HCV in liver disease. Proc Natl Acad Sci 1992;
89(21):10011–5.
5. Stokes JH. Epidemic infectious jaundice and its relarion to the therapy
of syphilis. Archives of Internal Medicine American Medical Association 20. Kleinman S, Alter H, Busch M, Holland P, Tegtmeier G, Nelles M, et al.
1920; 1;26(5):521–43. Increased detection of hepatitis C virus (HCV)-infected blood donors by
a multiple-antigen HCV enzyme immunoassay. Transfusion 1992;
6. Blumberg BS, Alter HJ, Visnich S. A “new” antigen in leukemia sera. 32(9):805–13.
JAMA American Medical Association 1965;191(7):541–6.
21. Grakoui A, Wychowski C, Lin C, Feinstone SM, Rice CM. Expression and
7. Alter HJ, Holland PV, Purcell RH, Lander JJ, Feinstone SM, Morrow AG, identification of hepatitis C virus polyprotein cleavage products. J Virol.
et al. Posttransfusion hepatitis after exclusion of commercial and he- American Society for Microbiology Journals 1993; 67(3):1385–95.
patitis-B antigen-positive donors. Ann Intern Med. 1972 ; 77(5):691–
9. 22. Lin C, Lindenbach BD, Prágai BM, McCourt DW, Rice CM. Processing in
the hepatitis C virus E2-NS2 region: identification of p7 and two distinct
8. Feinstone SM, Kapikian AZ, Purceli RH. Hepatitis A detection by immune E2-specific products with different C termini. J Virol 1994; 68(8):5063–
electron microscopy of a viruslike antigen associated with acute illness. 73.
Science 1973; 182(4116):1026–8.
23. Dubuisson J, Hsu HH, Cheung RC, Greenberg HB, Russell DG, Rice CM.
9. Feinstone SM, Kapikian AZ, Purcell RH, Alter HJ, Holland PV. Transfu- Formation and intracellular localization of hepatitis C virus envelope
sion-associated hepatitis not due to viral hepatitis type A or B. N Engl glycoprotein complexes expressed by recombinant vaccinia and Sindbis
J Med. 1975; 292(15):767–70. viruses. J Virol 1994; 68(10):6147–60.
10. Alter HJ. The dominant role of non-A, non-B in the pathogenesis of 24. Grakoui A, McCourt DW, Wychowski C, Feinstone SM, Rice CM. A second
post-transfusion hepatitis: a clinical assessment. Clin Gastroenterol hepatitis C virus-encoded proteinase. Proc Natl Acad Sci 1993;
1980; 9(1):155–70. 90(22):10583–7.
11. Houghton M. The long and winding road leading to the identification 25. Lin C, Rice CM. The hepatitis C virus NS3 serine proteinase and NS4A
of the hepatitis C virus. J Hepatol 2009; 51(5):939–48. cofactor: establishment of a cell-free trans-processing assay. Proc Natl
Acad Sci 1995; 92(17):7622–6.
12. He LF, Alling D, Popkin T, Shapiro M, Alter HJ, Purcell RH. Determining
the size of non-A, non-B hepatitis virus by filtration. J Infect Dis. 1987; 26. Kolykhalov AA, Agapov EV, Blight KJ, Mihalik K, Feinstone SM, Rice
156(4):636–40.
13. Feinstone SM, Mihalik KB, Kamimura T, Alter HJ, London WT, Purcell
RH. Inactivation of hepatitis B virus and non-A, non-B hepatitis by chlo-
roform. Infect Immun. American Society for Microbiology Journals 1983;
41(2):816–21.
Sesión científica celebrada el 26 de noviembre de 2020 para conmemorar
297los premios Nobel en fisiología o medicina y en química 2020
Juan Ramón Lacadena, Pablo Gastaminza, Lluis Montoliu
An. Real Acad. Farm. Vol. 86. Nº4 (2020) · pp. 287 - 310
